Advertisement

Targeted Oncology

, Volume 13, Issue 4, pp 533–539 | Cite as

Niraparib: A Review in Ovarian Cancer

  • Young-A Heo
  • Sean T. Duggan
Adis Drug Evaluation

Abstract

Niraparib (Zejula®), a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for the maintenance treatment of recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. Approval was based on the results of the randomized, double-blind, placebo-controlled phase III NOVA trial. In NOVA, niraparib significantly prolonged progression-free survival (primary endpoint), chemotherapy-free interval and time to first subsequent therapy compared with placebo in patients with recurrent, platinum-sensitive, high grade serous ovarian, fallopian tube or primary peritoneal cancer. The beneficial effects of niraparib were consistent regardless of BRCA mutation or homologous recombination deficiency (HRD) status. Niraparib had a manageable tolerability profile, with the majority of grade 3 or 4 adverse events being haematologic abnormalities (e.g. thrombocytopenia, anaemia, neutropenia). Adverse events were generally well managed with dose interruption or modification of niraparib. Current evidence suggests that niraparib is an effective new option with a manageable tolerability profile for the maintenance treatment of recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults, with or without BRCA1/2 mutation or HRD.

Notes

Acknowledgments

During the peer review process, the manufacturer of niraparib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of Interest

Young-A Heo and Sean Duggan are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    Erickson BK, Conner MG, Landen CN Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209(5):409–14.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;  https://doi.org/10.1038/s41467-017-00962-1.
  3. 3.
    National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (NCCN clinical practice guidelines in oncology). 2018. http://www.nccn.org/. Accessed 10 May 2018.
  4. 4.
    Cortez AJ, Tudrej P, Kujawa KA, et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38.CrossRefPubMedGoogle Scholar
  5. 5.
    Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384(9951):1376–88.CrossRefPubMedGoogle Scholar
  6. 6.
    Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol. 2014;26(5):521–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i40–i4.CrossRefPubMedGoogle Scholar
  8. 8.
    Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92.CrossRefPubMedGoogle Scholar
  9. 9.
    TESARO Inc. Zejula® (niraparib): US prescribing information 2017. http://www.fda.gov. Accessed 27 June 2018.
  10. 10.
    European Medicines Agency. Zejula (niraparib) 100 mg hard capsules: summary of product characteristics. 2018. http://www.ema.europa.eu/. Accessed 27 June 2018.
  11. 11.
    Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009;52(22):7170–85.CrossRefPubMedGoogle Scholar
  12. 12.
    AlHilli MM, Becker MA, Weroha SJ, et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol. 2016;143(2):379–88.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    European Medicines Agency. Zejula: European Public Assessment Report 2017. http://www.ema.europa.eu/. Accessed 27 Dec 2017.
  14. 14.
    Moore K, Zhang ZY, Agarwal S, et al. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018;81(3):497–503.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang ZY, Kansra V, Van Andel L, et al. Characterization of absorption, metabolism, and elimination of niraparib, an investigational poly (adp-ribose) polymerase inhibitor, in cancer patients [abstract]. Clin Ther. 2017;39(8 Suppl 1):e7–8.CrossRefGoogle Scholar
  16. 16.
    van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investig New Drugs. 2017;35(6):751–65.CrossRefGoogle Scholar
  17. 17.
    Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;  https://doi.org/10.1093/annonc/mdy181.
  20. 20.
    Matulonis UA, Herrstedt J, Tinker A, et al. Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC) [abstract no. 5534]. J Clin Oncol. 2017;35(15 Suppl 1):5534.CrossRefGoogle Scholar
  21. 21.
    Mahner S, Mirza MR, Moore K, et al. ENGOT-OV16/NOVA: results of secondary efficacy endpoints of niraparib maintenance therapy in ovarian cancer. Clin Adv Hematol Oncol. 2017;15(5 Suppl 5):2–3.Google Scholar
  22. 22.
    Fabbro M, Moore K, Dørum A, et al. Safety and efficacy of niraparib in elderly patients (pts) with recurrent ovarian cancer (OC) [abstract no. 934PD]. Ann Oncol. 2017;28(Suppl 5):v330–v54.Google Scholar
  23. 23.
    Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Ledermann J, Sessa C, Colombo N on behalf of the ESMO guidelines committee. eUpdate – ovarian cancer treatment recommendations 2016. http://www.esmo.org. Accessed 19 Mar 2018.
  25. 25.
    National Institue for Health and Care Excellence. Final appraisal determination: niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. 2018. http://www.nice.org.uk. Accessed 5 June 2018.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations